ClinicalTrials.gg
RecruitingNCT06503718FFDUpdated Jul 16, 2024

Management of Closed Diaphyseal Displaced Leg Fractures in Children and Adolescents

An observational study in Tibial Fractures, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 1 Year to 17 Years. Per ClinicalTrials.gov, last updated 2024-07-16.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
130
Ages
1 Year to 17 Years
Sex
All
01

Study summary

Most displaced tibial shaft fractures in pediatric patients have traditionally been treated after reduction by cast immobilization with good long-term results. Recently, there has been a growing trend towards surgical intervention by osteosynthesis from the outset. This study aims to describe the results of orthopedic treatment and osteosynthesis from the outset.

02

Conditions studied

  • Tibial Fractures

Keywords

  • Tibial Fractures
  • Osteosynthesis, Fracture
  • Closed Fracture
03

In context

Tibial Fractures

136 studies on the registry are indexed under Tibial Fractures; 38 are open to participants now.

This study's planned enrollment of 130 is above the median of 70 across 37 observational studies indexed under Tibial Fractures.

Browse Tibial Fractures studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Minor subject (under 18 years old) treated at the HUS, between June 1, 2004 and April 31, 2024, for a fracture of the displaced diaphysis of the tibia treated orthopedically or by osteosynthesis reviewed after more than 6 months

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Minor subject (under 18 years old)
  • Subject treated at the HUS, between June 1, 2004 and April 31, 2024, for a fracture of the displaced diaphysis of the tibia treated orthopedically or by osteosynthesis reviewed after more than 6 months
  • Absence of written opposition in the medical file of the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.

Exclusion criteria

Exclusion criteria:

  • Presence of opposition from the subject (and/or their legal representative if applicable) to the reuse of their data for scientific research purposes.
  • Non-displaced and/or displaced fracture not located at the level of the tibial diaphysis
  • Open fracture
  • Incomplete or unusable file
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
130 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Evaluation of the result of orthopedic treatment and osteosynthesis from the outset

    Use of the functional score for this assessment : Scores : * 95-100 : Excellent * 75-94 : Good * 51-74 : Fair * 0-50 : Poor

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Dec 2024, 8 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 16, 2024
StartActual
Apr 3, 2024
Primary completionEst.
Dec 2024
CompletionEst.
Dec 31, 2024
Last update
Jul 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06503718
Responsible party
Sponsor
First posted
Jul 16, 2024
Start date
Apr 3, 2024
Primary completion
Dec 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jul 16, 2024

Study contacts

Philippe GICQUEL, MD
Contact
Philippe.Gicquel@chru-strasbourg.fr
33 3 88 12 82 65

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion